Just Published: UTE T2* mapping of tendinopathic patellar tendons

Just Published: UTE T2* mapping of tendinopathic patellar tendons

UTE T2* mapping of tendinopathic patellar tendons: an MRI reproducibility study

There is currently a lack of imaging modalities that can be used as a sensitive measure in tendinopathy.

Tendinopathy, also called tendinosis, refers to the breakdown of collagen in a tendon. This causes burning pain in addition to reduced flexibility and range of motion. While tendinopathy can affect any tendon, it’s more common in the: Achilles tendon. rotator cuff tendons.

As newer imaging becomes available, it is important to assess its sensitivity and reproducibility of the measurements.

Recent findings suggest the applicability of ultra-short echo time (UTE) magnetic resonance imaging (MRI) T2* mapping in tendons.

These data demonstrate a small bias between repeated measurements for UTE T2*, but with a very low associated mean difference (3.7%) between the two tests.

The high ICC values and low typical error % demonstrate reproducibility of repeated T2*-mapping sessions.

The method showed substantial intra- and inter-observer reproducibility for T2* values proving feasibility for use of UTE T2* mapping in research and clinical practice.

Title: UTE T2* mapping of tendinopathic patellar tendons: an MRI reproducibility study.

Journal: Acta Radiologica 2021 Feb; 62(2):215-224

Authors: Anne-Sofie Agergaard, Nikolaj M Malmgaard-Clausen, Rene B Svensson, Janus D Nybing, Mikael Boesen, Michael Kjaer, S Peter Magnusson, Philip Hansen

Access Online: https://journals.sagepub.com/doi/10.1177/0284185120918807

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events